ABRYSVO Powder and solvent for solution for injection Ref.[51247] Active ingredients: RSV glycoprotein F antigen

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Product name and form

Abrysvo powder and solvent for solution for injection.

Respiratory syncytial virus vaccine (bivalent, recombinant).

Pharmaceutical Form

Powder and solvent for solution for injection.

The powder is white.

The solvent is a clear, colourless liquid.

Qualitative and quantitative composition

After reconstitution, one dose (0.5 mL) contains:

RSV subgroup A stabilised prefusion F antigen1,2 60 micrograms

RSV subgroup B stabilised prefusion F antigen1,2 60 micrograms

(RSV antigens)

1 glycoprotein F stabilised in the prefusion conformation
2 produced in Chinese Hamster Ovary cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

Active Ingredient Description
RSV glycoprotein F antigen

RSV glycoprotein F antigen is designed to enhance antigen-specific cellular immune response and neutralizing antibodies response in individuals with pre-existing immunity against RSV. The adjuvant AS01E facilitates the recruitment and activation of antigen presenting cells carrying vaccine-derived antigens in the draining lymph node, which in turn leads to the generation of RSVPreF3-specific CD4+ T cells.

List of Excipients

Powder:

Trometamol
Trometamol hydrochloride
Sucrose
Mannitol
Polysorbate 80
Sodium chloride
Hydrochloric acid (for pH adjustment)

Solvent:

Water for injections

Pack sizes and marketing

Powder:

Powder for 1 dose in a vial (type 1 glass or equivalent) with a stopper (synthetic chlorobutyl rubber) and a flip off cap.

Solvent:

Solvent for 1 dose in a pre-filled syringe (type 1 glass) with a stopper (synthetic chlorobutyl rubber) and a tip cap (synthetic isoprene/bromobutyl blend rubber).

Vial adaptor:

Sterile vial adaptor.

Pack size:

Pack containing 1 vial of powder, 1 pre-filled syringe of solvent, 1 vial adaptor with 1 needle or without needles.

Pack containing 5 vials of powder, 5 pre-filled syringes of solvent, 5 vial adaptors with 5 needles or without needles.

Pack containing 10 vials of powder, 10 pre-filled syringes of solvent, 10 vial adaptors with 10 needles or without needles.

Not all pack sizes may be marketed.

Marketing authorization holder

Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Marketing authorization dates and numbers

EU/1/23/1752/001 – 1 vial, 1 vial adaptor, 1 pre-filled syringe, 1 needle
EU/1/23/1752/002 – 1 vial, 1 vial adaptor, 1 pre-filled syringe
EU/1/23/1752/003 – 5 vials, 5 vial adaptors, 5 pre-filled syringes, 5 needles
EU/1/23/1752/004 – 5 vials, 5 vial adaptors, 5 pre-filled syringes
EU/1/23/1752/005 – 10 vials, 10 vial adaptors, 10 pre-filled syringes, 10 needles
EU/1/23/1752/006 – 10 vials, 10 vial adaptors, 10 pre-filled syringes

Drugs

Drug Countries
ABRYSVO Austria, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Romania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.